Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Fotsch

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Journal of Medicinal Chemistry|July 9, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocketFang-Tsao Hong, Mark H Norman, Kate S Ashton, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2010
Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonistsQingyian Liu, Wenyuan Qian, Aiwen Li, et al.
Journal of Medicinal Chemistry|December 4, 2013
Piperazine oxadiazole inhibitors of acetyl-CoA carboxylaseMatthew P Bourbeau, Aaron Siegmund, John G Allen, et al.
Journal of Medicinal Chemistry|January 7, 2005
Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamidesElizabeth M Doherty, Christopher Fotsch, Yunxin Bo, et al.
Chemical Research in Toxicology|January 26, 2010
Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screeningRaju Subramanian, Matthew R Lee, John G Allen, et al.
Journal of Medicinal Chemistry|June 26, 2007
Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamidesMark H Norman, Jiawang Zhu, Christopher Fotsch, et al.
Journal of Medicinal Chemistry|June 9, 2006
Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazolesVassil I Ognyanov, Chenera Balan, Anthony W Bannon, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamidesChristopher Fotsch, Nianhe Han, Premilla Arasasingham, et al.
Journal of Medicinal Chemistry|June 26, 2007
Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidateElizabeth M Doherty, Christopher Fotsch, Anthony W Bannon, et al.
Journal of Medicinal Chemistry|April 28, 2015
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational AnalysisNuria A Tamayo, Mark H Norman, Michael D Bartberger, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Journal of Medicinal Chemistry|July 9, 2014
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocketFang-Tsao Hong, Mark H Norman, Kate S Ashton, et al.
Bioorganic & Medicinal Chemistry Letters|June 25, 2010
Aryl sulfonamides containing tetralin allylic amines as potent and selective bradykinin B1 receptor antagonistsQingyian Liu, Wenyuan Qian, Aiwen Li, et al.
Journal of Medicinal Chemistry|December 4, 2013
Piperazine oxadiazole inhibitors of acetyl-CoA carboxylaseMatthew P Bourbeau, Aaron Siegmund, John G Allen, et al.
Journal of Medicinal Chemistry|January 7, 2005
Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamidesElizabeth M Doherty, Christopher Fotsch, Yunxin Bo, et al.
Chemical Research in Toxicology|January 26, 2010
Cytochrome P450-mediated epoxidation of 2-aminothiazole-based AKT inhibitors: identification of novel GSH adducts and reduction of metabolic activation through structural changes guided by in silico and in vitro screeningRaju Subramanian, Matthew R Lee, John G Allen, et al.
Journal of Medicinal Chemistry|June 26, 2007
Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamidesMark H Norman, Jiawang Zhu, Christopher Fotsch, et al.
Journal of Medicinal Chemistry|June 9, 2006
Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazolesVassil I Ognyanov, Chenera Balan, Anthony W Bannon, et al.
Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Melanocortin subtype-4 receptor agonists containing a piperazine core with substituted aryl sulfonamidesChristopher Fotsch, Nianhe Han, Premilla Arasasingham, et al.
Journal of Medicinal Chemistry|June 26, 2007
Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidateElizabeth M Doherty, Christopher Fotsch, Anthony W Bannon, et al.
Journal of Medicinal Chemistry|April 28, 2015
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational AnalysisNuria A Tamayo, Mark H Norman, Michael D Bartberger, et al.
Pageof 5